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Abstract
Background: Dual-chamber (DDD) pacing is the most widely utilised pacing modality in many 
parts of the world. The present study aimed to evaluate life expectancy of DDD pacemaker patients in 
comparison to the age- and sex-matched general population, assess changes in baseline characteristics 
over three decades of the inclusion period and determine the association between selected variables and 
patient survival.
Methods: This longitudinal study of consecutive de novo DDD pacemaker implantations performed 
between 1984 and 2014, with all-cause mortality until 2016 as the endpoint, was conducted at a single-
center university hospital. 
Results: Under assessment were 3928 patients with a total of 30,087 patient-years of survival time. 
Compared to the general population, the observed survival was significantly inferior until 12 years post 
DDD pacemaker implant (HR = 1.499, p < 0.001), whereas after 12 years of follow-up the observed 
survival was significantly superior (HR = 0.555, p < 0.001). A comparison of  patient baseline charac-
teristics over three decades revealed the following significant changes: more elderly patients, more female 
patients, less patients with atrioventricular block, more patients with atrial fibrillation/atrial flutter 
(AF/AFL) and fewer patients with an apical right ventricular (RV) lead position in the later decades. 
In multivariate analysis male sex and higher age were the only variables significantly associated with 
shorter survival time. Indication for pacing, history of pre-implant AF/AFL, RV lead position and device 
infection were not associated with survival.
Conclusions: In the very-long-term follow-up of DDD pacemaker patients, the parameters associated 
with survival were sex and baseline age at first implantation. (Cardiol J 2019; 26, 6: 717–726)
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Introduction
Population-based observational studies and 
randomized controlled trials have assessed long-
term survival and a variety of factors for their 
prognostic importance after pacemaker (PM) 
implant. Evaluated risk factors included baseline 
factors such as patient gender, age at implantation, 
decade of implantation, type of bradyarrhythmia, 
presence of atrial fibrillation (AF), cardiovascular 
diseases, non-cardiac comorbidities and periproce-
dural factors such as type of pacing mode, urgency 
of the procedure, position of the right ventricular 
(RV) lead and necessity of temporary pacing 
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[1–6]. Results have varied depending on popula-
tion sample size, baseline characteristics, enrol-
ment criteria, length of follow-up and the choice 
of evaluated factors. Currently, dual-chamber 
(DDD) pacing is by far the most widely utilized 
pacing modality in clinical practice in many parts 
of the world, and its use is exhibiting an increas-
ing trend [7–9]. According to the 2013 European 
Society of Cardiology (ESC) guidelines, DDD pac-
ing mode is the first choice in patients with sick 
sinus syndrome (SSS) and atrioventricular block 
(AVB) [10]. Despite its widespread use, the very-
long-term survival of patients with DDD PMs has 
not been addressed separately from other pacing 
modalities in an analysis of an unselected, real-
world cohort. Therefore, the present aim was to 
examine prognostic impact of selected variables on 
survival time and overall mortality of the DDD PM 
population compared to an age- and sex-matched 
population. Moreover, patient profiles and long-
term survival outcomes were compared after DDD 
PM implantation across three successive decades 
at a single center.
Methods 
The study cohort consisted of all consecu-
tive patients who underwent de novo DDD PM 
implantation between 4 October 1984 (first DDD 
PM implantation) and 31 December 2014 at a high-
volume, third-level reference university implanta-
tion center. Each patient was followed up after PM 
implantation up to 31 August 2016 or the time of 
death before 1 September 2016. The data of patient 
survival status and deceased patient date of death 
were collected from the national death registration 
system. Information on death dates was available 
up until the end of August 2016. The endpoint was 
all-cause mortality. The data used in the analysis 
included (1) patient demographic baseline char-
acteristics: date of birth, age at implantation and 
sex; (2) index arrhythmia (anti-bradycardia pacing 
indication): AVB defined as third-degree AVB, 
second-degree AVB and intraventricular conduc-
tion abnormalities (bundle branch block and/or 
fascicular block) with syncope or symptomatic SSS; 
(3) history of atrial fibrillation/atrial flutter (AF/ 
/AFL) prior to DDD PM implantation; (4) position 
of the RV lead: apical or non-apical at discharge 
from the department; (5) time of device-related 
infection onset and (6) date of death declared in the 
death certificate. This information was retrospec-
tively gathered from paper and electronic medical 
records of hospitalizations when DDD PM implan-
tation was performed, operative reports and outpa-
tient pacemaker clinic records. If the patients had 
various coexisting types of bradyarrhythmia, the 
following priority ranking was applied for assign-
ing the main indication for anti-bradycardia pacing: 
third-degree AVB, second-degree AVB, SSS and 
finally intraventricular conduction abnormality 
(bundle branch block and/or fascicular block) 
with syncope in case there was no other cause of 
syncope. SSS was represented by sinoatrial block, 
sinus node arrest, tachycardia–bradycardia syn-
drome and chronotropic incompetence. The term 
‘history of AF/AFL’ was defined as AF and/or AFL 
documented on electrocardiogram prior to DDD 
PM implantation and included paroxysmal and 
persistent AF and/or AFL provided that the res-
toration of sinus rhythm was planned after DDD 
PM implantation. Patients with permanent AF/ 
/AFL were referred for VVI PMs throughout the 
study period. Device-related infection included 
local device infection and cardiac device-related 
infective endocarditis. The position of the RV 
lead was determined from operative reports and 
postprocedure, posteroanterior and left lateral 
chest radiographs.
Regarding the RV lead implantation tech-
nique, on a year-over-year basis, we specified the 
periods when RV apical lead fixation prevailed and 
when non-apical localizations were utilized more 
frequently. The implantation period 1984–2014 
was divided into three successive time intervals 
referred to as decades: the first decade was from 
1 October 1984 to 31 December 1994, the second 
was from 1 January 1995 to 31 December 2004 and 
the third was from 1 January 2005 to 31 December 
2014. On a decade-over-decade basis, the number 
of patients, their baseline characteristics at the 
time of implantation and the type of RV lead posi-
tion were compared. 
Regarding survival data, the total duration 
between the first DDD PM implantation and either 
the date of death or end of the follow-up period 
(31 August 2016) was calculated for the whole 
cohort and referred to as patient-years of survival 
time. Additionally, life expectancy tables provided 
by Central Statistical Office for Poland for years 
1990–2014 to match each person in the cohort 
with the age- and sex-matched life expectancy 
predicted at the year of DDD PM implantation were 
used [11]. Patients who underwent implantation 
between 1984 and 1989 were matched with the 
life expectancy predicted in 1990. The end date 
of follow-up which is 31 August 2016 was used to 
censor expected survival.
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Statistical analysis
The data were evaluated using IBM SPSS 
Statistics for Windows, Version 25 (IBM Corp., 
Armonk, NY, USA). Normality was tested using 
Shapiro-Wilk test for samples less than or equal 
to 2000 and Kolmogorov-Smirnov test for samples 
greater than 2000. Continuous variables are ex-
pressed as mean, standard deviation and addition-
ally as median and interquartile range (IQR) for 
variables with non-normal distribution. Groups were 
compared using the c2 test for discrete variables and 
the Mann-Whitney U test for continuous variables 
with non-normal distribution. Event-free rates were 
calculated using the Kaplan-Meier analysis method 
and compared using the log-rank test. The asso-
ciations between patient survival and the selected 
variables were assessed using a Cox proportional 
hazards model and presented as hazard ratio (HR) 
with 95% confidence interval (CI). The associations 
between patient survival and variables with time-
varying effect (strength of a factor was not constant 
over time) and time-varying covariates (value of the 
factor was not constant over time) were tested using 
Cox model with time-dependent covariate. A p value 
of < 0.05 was considered statistically significant.
Results
A total of 3932 consecutive patients underwent 
primary DDD PM implantation during the study pe-
riod. The data of patient survival status on the last 
day of follow-up were available for 3928 (99.9%) 
patients. Four (0.1%) patients were excluded from 
the analysis due to unverified survival status be-
cause of unavailability of an identification number. 
Notably, for all  baseline variables considered in 
the study population (3928 patients), there was 
no missing data.
The patient baseline clinical characteristics 
and a comparison of data from successive decades 
of DDD PM implantation are presented in Table 1. 
The mean age at the time of implantation was 
69.8 ± 12.1, median (IQR) 71.9 (14.2), range 15.3–96.6 
years; 53.7% of patients were male; 2610 (66.4%) 
patients had SSS; 1318 (33.6%) patients had 
AVB defined as third-degree AVB (552 patients), 
second-degree AVB (737 patients) and bundle 
branch block with syncope (28 patients). AF/AFL 
before implantation was observed in 1318 (33.6%) 
patients. Women were older than men at the time 
of implantation: 70.5 ± 11.7, median (IQR) 72.6 
(13.1) vs. 69.2 ± 12.4, median (IQR) 71.2 (14.8) 
years (p < 0.001); patients with SSS were older 
than those with AVB: 70.4 ± 11.2, median (IQR) 
72.2 (13.2) vs. 68.6 ± 13.7, median (IQR) 71.3 
(16.1) years (p = 0.004); and patients with a his-
tory of AF/AFL were older than AF/AFL-free 
patients: 71.9 ± 10.1, median (IQR) 73.0 (12.0) 
vs. 68.7 ± 12.9, median (IQR) 71.2 (15.2) years 
(p < 0.001). AVB was present in 25.6% of women 
Table 1. Comparison of the patient baseline characteristics across three successive decades of DDD 
pacemaker implantations.
Total 
population
1st decade
X 1984 – XII 1994
2nd decade
I 1995 – XII 2004
3rd decade
I 2005 – XII 2014
P
Number of patients 3928 (100%) 210 (5.3%) 1144 (29.1%) 2574 (65.5%)
Age [years]: < 0.001
0–50 290 (7.4%) 41 (19.5%) 135 (11.8%) 114 (4.4%)
51–70 1537 (39.1%) 127 (60.5%) 531 (46.4%) 879 (34.1%)
71–80 1498 (38.1%) 33 (16.7%) 400 (35.0%) 1065 (41.4%)
81–90 576 (14.7%) 8 (3.8%) 76 (6.6%) 492 (19.1%)
> 90 27 (0.7%) 1 (0.5%) 2 (0.2%) 24 (0.9%)
Mean age at implantation 
[years]
69.8 ± 12.1 61.0 ± 13.5 66.5 ± 12.0 72.0 ± 11.3 < 0.001
Female sex 1817 (46.3%) 88 (41.9%) 502 (43.9%) 1227 (47.7%) 0.045
Atrioventricular block 1318 (33.6%) 113 (53.8%) 296 (25.9%) 909 (35.3%)
< 0.001
Sick sinus syndrome 2610 (66.4%) 97 (46.2%) 848 (74.1%) 1665 (64.7%)
History of atrial fibrillation/ 
/atrial flutter 
1318 (33.6%) 22 (10.5%) 299 (26.1%) 997 (38.7%) < 0.001
Right ventricular lead apical 
position
1693 (43.1%) 210 (100%) 1107 (96.8%) 376 (14.6%) < 0.001
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and 44.4% of men (p < 0.001). The prevalence 
of AF/AFL before implantation reached 40.9% in 
women and 27.2% in men (p < 0.001). From 1984 
to 2005, the majority of RV leads were placed 
at the RV apex, and from 2006, the majority of 
RV leads were placed in a non-apical position. 
A comparison of baseline characteristics among 
the three successive decades revealed a signifi-
cant rise in number of procedures, average age 
at implantation, number of women referred for 
DDD PM, prevalence of SSS and prevalence of AF/ 
/AFL prior to implantation (Table 1). Furthermore, 
stratification of patients by age group disclosed 
a significant decreasing trend in the proportion of 
patients before or in the seventh decade of life and 
an increasing trend in the proportion of patients in 
eighth, ninth and tenth decades of life (p < 0.001).
A total of 30,087 patient-years of survival time 
was calculated for 3928 patients. The mean obser-
vation time was 7.7 ± 5.3, median (IQR) 6.4 (6.7) 
years. During the follow-up period 1435 (36.5%) 
patients died. The mean age of the deceased pa-
tients was 79.9 ± 9.7, median (IQR) 81.6 (11.3) 
years. The Kaplan-Meier estimates for survival 
probability after DDD PM implantation at 1, 2, 5, 
10, 15 and 20 years after the procedure amounted 
to 96%, 92%, 82%, 62%, 46% and 32%, respective-
ly. With regard to age- and sex-matched survival 
data, the predicted number of deaths amounted 
to 1262 (32.1%) and predicted mean observation 
time was 8.4 ± 4.6, median (IQR) 7.4 (5.8) years. 
The expected survival curve had a reverse sig-
moidal shape and crossed the observed survival 
at 12 years after implantation. Until 12 years of 
follow-up the observed risk of death was higher 
than expected (HR = 1.499, 95% CI 1.376–1.633, 
p < 0.001), whereas after 12 years observed mor-
tality was lower than expected (HR = 0.555, 95% 
CI 0.468–0.658, p < 0.001) (Fig. 1). The Kaplan-
-Meier curves revealed no significant difference in 
survival with regard to index arrhythmia (AVB vs. 
SSS; p = 0.92) (Fig. 2A) and a history of AF/AFL 
before implantation (p = 0.503) (Fig. 2B). Male 
sex was associated with unfavourable survival 
(p < 0.001) (Fig. 2C). Patients with apical RV lead 
position compared to patients with non-apical lead 
position had a significantly better survival during 
the first 10 years after implantation (p = 0.002) 
(Fig. 3A). With regard to the time of implantation, 
the later the decade of implantation the worse 
survival was observed with statistically significant 
linear trend for factor levels (p < 0.001) (Fig. 4A). 
However, after survival adjustment for sex and age 
at implantation the difference in survival between 
apical and non-apical RV lead position group was 
attenuated (p = 0.196) (Fig. 3B). Furthermore, 
survival during 10 years after implantation after 
adjustment to sex and age was superior in patients 
with implantation in third decade compared to 
patients with implantation in second decade (p = 
= 0.017). Comparing sex- and age-adjusted sur-
vival curves for first vs. second decade and first vs. 
third decade there were no statistically significant 
differences (Fig. 4B).
The Cox proportional hazard regression model 
demonstrated that older age at implantation and 
male sex were significantly associated with higher 
mortality. By contrast, pacing indication and a his-
tory of AF/AFL were not associated with survival 
(Fig. 5). 
During follow-up 43 (1.1%) patients, 20 fe-
males, developed device-related infection after 
a mean follow-up of 7.3 ± 5.3, median (IQR) 7.2 
(8.7) years. Twenty-six (60.4%) patients with local 
infections were observed and 17 (39.5%) patients 
with cardiac-device related infective endocarditis. 
Within 1 year from implantation 6 (14%) patients 
developed device-related infections. Death oc-
curred in 14 (32.6%) patients, 5 females, after 
a mean period of 9.2 ± 6.0, median (IQR) 8.4 (6.8) 
years from infection diagnosis. Device-related in-
fection was not associated with an increased risk of 
death (HR = 0.693, 95% CI 0.097–4.93, p = 0.714). 
Figure 1. Survival of patients with DDD pacemaker rela-
tive to the age- and sex-matched general population. 
HR — hazard ratio; CI — confidence interval.
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population. Therefore, the present study, which 
had an excellent (99.9%) rate of complete data on 
overall survival, was designed to allow comparisons 
in a large group of consecutive patients enrolled 
without exclusion criteria who received a DDD PM 
at a single center and were free from permanent 
AF/AFL at the moment of implantation. With 3928 
patients, 30,087 patient-years of survival time and 
an observation time of three decades, this is one of 
Figure 2. Survival of patients with atrioventricular block (AVB) relative to patients with sick sinus syndrome (SSS) (A), 
survival of patients with a history of atrial fibrillation/atrial flutter (AF/AFL) relative to patients without pre-implant 
AF/AFL (B), survival of women relative to men (C).
Discussion
The long-term survival of PM patients has 
been assessed in several population-based studies 
of general PM populations that included from 1.5% 
to 73.3% patients with DDD PM [1, 2, 4, 5, 12–14]. 
Importantly, no study has analysed mortality in 
very-long-term DDD PM patients only, or identi-
fied independent risk factors for mortality in this 
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the largest studies to reliably examine very-long- 
-term survival in patients referred for primary 
DDD PM implantation. 
In reports on survival of a PM population, 
authors have concluded that prognosis of PM 
recipients without significant comorbidities at 
baseline approached that of the general population 
[1, 5, 13, 14]. Among the factors contributing most 
to increased mortality in the PM group relative to 
the control population were significant non-cardiac 
Figure 3. Survival during 10 years after implantation in patients with right ventricular (RV) lead in apical position rela-
tive to patients with RV lead in non-apical position (A), survival after adjustment for age and sex (B).  
Figure 4. Survival during 10 years after implantation according to the decade of implantation (A), survival after adjust-
ment for age and sex (B).
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comorbidities and structural heart disease [1, 5, 
13, 14]. Pyatt et al. [4] have reported significantly 
higher overall mortality in PM cohort compared 
to expected mortality during a period of 8 years 
after implantation. The present data, showing 
significantly worse overall survival in DDD cohort 
relative to the expected survival until 12 years after 
implantation are in agreement with the results of 
Pyatt et al. [4]. On the other hand, after 12 years 
post-implant survival among DDD recipients 
significantly exceeded survival of general popula-
tion. Presumably, long-term benefit from DDD PM 
beyond 12 years of follow-up might have applied 
predominantly to a population without significant 
comorbidities and were relatively young at base-
line. Reasons for improved survival after 12 years, 
post-implant in DDD PM patients, might have in-
cluded prevention against sudden bradyarrhythmic 
death and regular follow-up with cardiologist which 
might have allowed early recognition and treatment 
of cardiovascular diseases.
The 1-year survival rate of the present DDD 
cohort was 96%. These data appear to accord with 
1-year overall survival rates from 90.5% to 96% 
as provided in reports of DDD populations [4, 12, 
15, 16] and rates from 91% to 94% as provided 
in reports of general PM populations [1, 5, 13, 
14]. At 5-year follow-up, cumulative survival rate 
was 82%. Reported 5-year survival rate of DDD 
cohorts was significantly lower and accounted 
for 58% to 64.7% [4, 12, 17], whereas in general 
PM cohorts, this value reached 58.2% to 69% 
[2, 5, 18]. Long-term estimated survival probability 
at 10-year follow-up after implantation was 62%, 
which is broadly consistent with other reports of 
general PM populations: from 44.8% to 75.4% 
[2, 13]. The 20-year survival probability was esti-
mated at 32% in the present study compared with 
21.4% observed by Brunner et al. [2]. Importantly, 
in the study Brunner et al. [2], a significant number 
of patients (38.6%) were lost to follow-up and cen-
sored as alive on the day of their last visit, which 
renders their information on estimated survival 
rates less accurate.
Regarding baseline characteristics, a higher 
prevalence of men across the study period was 
observed, which is in accordance with the major-
ity of studies in DDD PM populations [15–17, 19] 
and general PM populations [1, 2, 5, 9, 12, 13, 18] 
except for Scandinavian populations, in which the 
prevalence of women receiving first DDD PM 
was reported to be higher than that of men [20, 
21]. In the present study, the prevalence of men 
exhibited a statistically significant decreasing 
trend from 58% in the first decade to 52% in the 
third decade, which is opposed to observations 
of a stable proportion of men in successive eras 
of PM implantation [1, 2]. The age of patients at 
first PM implantation increased with each decade, 
similar to a trend observed in western countries 
[2, 7, 18]. Furthermore, the present study identi-
fied a significant increase in PM utilization among 
older patients (> 70 years). In countries with 
advanced health systems, the percentage of PM 
recipients older than 80 years was > 30% and 
exhibited a significantly increasing trend [1, 8, 9, 
18]. Female patients were older than men at the 
time of implantation, as it has been observed in 
a majority of countries [1, 2, 8, 22], and were more 
likely to present with SSS [1, 2, 22]. There has 
Figure 5. Factors associated with survival in multivariable Cox regression model; AVB — atrioventricular block; 
SSS — sick sinus syndrome; AF/AFL — atrial fibrillation/atrial flutter; HR — hazard ratio; CI — confidence interval.
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been a shift in the main indications, with AVB being 
more prevalent in 1984–1994 and the domination 
of SSS in 1995–2014. Unlike the results herein, 
a higher incidence of high-grade AVB than of SSS 
throughout the study period has been frequently 
reported in general PM populations [1, 2, 4, 5, 9, 
12–14, 18]. Importantly, in the present study, the 
prevalence of pre-implant AF/AFL soared across 
the study period, reaching 39% in the third decade, 
a trend that can probably be attributed to enhanced 
detection of AF/AFL, increasing age of patients 
[23] and shift of indications towards SSS [20, 24].
The significant association between male 
sex and older age at baseline and worse survival 
has been noted previously [1, 2, 4, 5, 13] and cor-
responds to the fact that women generally have 
a longer life expectancy. As expected, the present 
study demonstrated that in the Cox regression 
model, age and male sex were independently asso-
ciated with mortality after primary DDD implanta- 
tion. For each additional year of age at implantation, 
a 7.8% increase in mean risk of death was observed; 
in the general PM population, this value has been 
reported as 5% to 9% [2, 4, 5, 12]. By contrast, 
no significant difference in survival with regard 
to either index arrhythmia or a history of AF/AFL 
was detected in the present study. The literature 
on the influence of index arrhythmia on survival 
comprises conflicting results. In a multivariate 
analysis of the study population, Brunner et al. 
[2] observed that SSS was associated with better 
survival than was AVB; however, on considering 
patients with first implantation during the last 
decade (1991–2000), this effect was no longer 
significant. Furthermore, Jahangir et al. [12] and 
Pyatt et al. [4] have identified that AVB is a risk 
factor for increased mortality compared with SSS 
[4, 12]. Conversely, Udo et al. [5], Mayosi et al. 
[14] and Jelić et al. [13] have demonstrated that 
survival of SSS and AVB patients is comparable.
In the FOLLOWPACE study, a history of atrial 
tachyarrhythmia was not an independent predictor 
of survival [5]. Conversely, Bradshaw et al. [1] 
demonstrated that a history of AF was significantly 
associated with reduced 1-year and 5-year survival. 
Of note, with  increasing patient age at implanta-
tion across the second and third decades, age- and 
sex-adjusted survival of patients displayed an 
improving trend. The available data indicate that 
either the later the first implantation occurs in the 
study period, the better the prognosis of the PM 
recipient [2] or that there is no association between 
the era of implantation and mortality [1]. Regard-
ing the RV lead position, after adjustment for sex 
and age at implantation there was no significant 
association with mortality. Witt et al. [6] assessed 
3450 unselected patients who underwent DDD 
PM implantation between 2004 and 2014, among 
whom the RV lead was positioned at the RV apex 
in the majority of patients (71.9%) and less com-
monly at the septum (6.9%) or other RV regions 
(21.2%). Authors reported that an apical RV lead 
position was associated with increased mortality 
compared with a septal position group (31% vs. 
24%, p = 0.02). Patients with very high levels of 
pacing, greater than 90%, had a significantly lower 
mortality rate in the septal pacing group (16% 
vs. 31%, p = 0.03), whereas patients with very 
low levels of pacing, less than 10%, did not have 
a significant difference in mortality (13% vs. 23%, 
p = 0.10) [6]. Due to the retrospective design of 
the present study and the findings of Witt et al. [6], 
none of the aforementioned results can be taken as 
a definitive answer to the long-debated question of 
whether an apical position of the RV pacing lead is 
worse than a non-apical position. 
In the present study, an infection rate of 1.1% 
per patient was observed, which is in line with 
previous reports from literature. Hercé et al. [25] 
in a study based on a registry which included 2496 
patients observed 35 (1.4%) cases with device-
related infections. Greenspon et al. [26] reported 
that the rate of device-associated infections in the 
United States rose from 1.53% in 2004 to 2.41% 
in 2008, likely due to an increase of patients with 
multiple comorbidities. Earlier reports on DDD 
PM population with implantation between 1984 
and 2002 showed the rate of device-related infec-
tion was less than or equal to 1.2% [27, 28]. The 
present study shows that device-related infection 
was not a risk factor for increased mortality dur-
ing follow-up and patients diagnosed with pacing 
system infection had relatively good long-term 
survival. Results herein, are in keeping with the 
findings of a prospective matched cohort-study 
of Deharo et al. [29] who observed no significant 
excess in all-cause long-term mortality in infection 
cohort compared with controls without device-
related infection.
Limitations of the study
The main limitation is the retrospective nature 
of this study, with all its inherent limitations. First, 
data regarding other baseline factors that possibly 
influenced survival, such as a history of concomi-
tant diseases, medications, functional status (New 
York Heart Association class) and urgency of the 
procedure (elective/emergency), were not com-
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plete for the whole population and were therefore 
not included in the analysis. Similarly, the percent-
age of RV pacing was not available for all patients, 
therefore the association between RV lead position 
and mortality could not be further analyzed in sub-
groups with different requirements of RV pacing. 
Second, the prevalence of pre-implant AF/AFL in 
the first two decades may have been underrated 
due to lower awareness and surveillance. Third, 
selection bias of presumably ‘sicker’ patients with 
AVB referred for single-chamber ventricular pacing 
could not be excluded and presumably ‘healthier’ 
patients with SSS to single-chamber atrial pac-
ing because evidence supporting the use of DDD 
systems as a first-choice pacing mode for both 
indications was unavailable at the time.
Conclusions
With an increasing number of DDD PM im-
plantations over time, a significant change in 
patient baseline characteristics was observed: 
average age at implantation continued to rise, 
more women were referred for implantation and 
the prevalence of AF/AFL prior to implantation 
grew rapidly. During 12 years after implantation, 
survival of the DDD cohort was significantly worse 
than in an age- and sex-matched general popula-
tion, however, after 12 years the survival of DDD 
recipients were significantly better than expected. 
Male sex and age were the only clinical variables 
associated with a shortened survival time and an 
increased probability of death. Indication for pacing, 
history of pre-implant AF/AFL, RV lead position 
and device-related infection were not associated 
with survival.
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